Most cell therapy manufacturing processes are initially developed using cells from healthy donors. The logic is straightforward — healthy cells are easier to work with, more consistent, and readily available. But this approach carries a significant risk: processes optimized for healthy cells can fail entirely when applied to cells from the patients who will actually receive the therapy.[1][2]
Disease-state donor samples — cells collected from patients with specific medical conditions — are essential for developing therapies that work in the real clinical setting. Understanding how to source, process, and work with these materials is increasingly recognized as a critical success factor in cell therapy development.[1]
What Are Disease-State Donor Samples?
Disease-state biospecimens are patient samples collected under IRB-approved protocols from individuals with specific diseases or medical conditions. These include peripheral blood mononuclear cells (PBMCs), leukopaks, whole blood, serum, and plasma from patients with conditions such as cancer (liquid and solid tumors), autoimmune diseases (lupus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, Crohn’s disease, psoriasis, celiac, etc.), COPD, osteoarthritis, and many others.
These samples come with comprehensive documentation including disease history, treatment background, inclusion and exclusion criteria compliance, and detailed demographic profiles — making them invaluable for therapy development programs that need to understand how their product will perform in the target patient population.
Why Healthy Donor Material Alone Is Not Enough
The case for incorporating disease-state materials early in development is supported by a growing body of published research and clinical experience.[1][2]
Manufacturing Processes May Fail with Patient Cells
A manufacturing process that consistently produces high-quality product from healthy donor cells may fail when applied to cells from a patient with active disease. Patients eligible for therapies like CAR-T have often been treated with multiple rounds of chemotherapy or radiation, which compromises T cell functionality. Their cells may show low fitness, high frequencies of exhausted effector phenotypes, and reduced proliferative capacity — none of which are captured in development work using healthy donors.[2][3]
Starting Material Variability Drives Manufacturing Failure
Published research indicates that the risk of manufacturing failure in autologous CAR-T cell products can reach approximately 25% for patients with non-Hodgkin lymphoma, with starting material quality identified as a primary root cause.[3] Patient-derived apheresis products contain variable levels of monocytes, granulocytes, and other contaminating cell populations. Increased monocyte counts are associated with reduced T cell expansion, while excess neutrophils may reduce transduction efficiency.[2] These variables are disease-dependent and cannot be predicted from healthy donor data alone.
Preclinical Data May Not Translate
Using healthy cells to study disease-specific mechanisms can produce misleading preclinical results. Therapies that showed promise in healthy donor models have failed to achieve desired outcomes in patients, sometimes with severe and unexpected toxicity. As published in Drug Target Review, developing cell therapies solely with healthy donor material can jeopardize clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures.[1]
The Unique Challenges of Processing Disease-State Samples
Working with disease-state materials is inherently more complex than working with healthy donor cells. Understanding these challenges is essential for sponsors and CDMOs designing robust manufacturing processes.
Lower and more variable cell counts. Patients with hematologic malignancies or autoimmune conditions frequently present with lymphopenia, limiting the amount of starting material available.[2][4] Each patient’s cellular composition differs based on disease burden, prior treatments, age, and individual biology.
Cell dysfunction and exhaustion. T cells from patients with active disease often exhibit exhausted phenotypes with reduced proliferative and cytotoxic capacity.[2][3] This is particularly relevant for autologous CAR-T programs where the patient’s own cells must be engineered to target cancer cells.
Contaminating cell populations. Apheresis starting material contains red blood cells, platelets, monocytes, and granulocytes that must be removed. The composition of these contaminating populations varies with disease state and can significantly impact downstream manufacturing success.[2]
Time-sensitive processing requirements. Disease-state samples often require rapid processing after collection — in some cases within hours of surgical resection for tumor-derived materials — to maintain viability and functional characteristics.[5]
What to Look for in a Disease-State Sample Provider
The quality and characterization of disease-state starting materials directly impacts the relevance and reliability of development work. When evaluating providers, sponsors should consider several key factors.
Breadth of disease coverage. A provider with access to donors across a wide range of disease indications — including both common conditions and rare diseases — offers more flexibility as programs evolve.
Donor characterization depth. Beyond basic disease diagnosis, look for providers that offer selection based on HLA type (Class I and II), CMV status, age, gender, treatment and medication history, and other relevant clinical parameters. The ability to select highly characterized donors enables more targeted and reproducible development work.
Recallable donor access. For longitudinal studies or programs requiring multiple collections from the same donor, access to a recallable donor pool is essential. This allows sponsors to obtain consistent starting material over time rather than relying on single-use anonymous donors.
IRB-approved protocols and regulatory compliance. All disease-state samples should be collected under IRB-approved protocols with proper informed consent that allows use for your specific application (e.g., in vivo animal models, genetic modification, modeling using artificial intelligence, etc.).
Flexible processing capabilities. A supplier with flexible processing capabilities can support both fresh and frozen workflows, helping teams align material format with assay timing, shipping constraints, and study design without compromising comparability. Just as important is the ability to isolate multiple cell types (e.g., PBMCs, NK cells, and T cells) and blood components (e.g., serum and plasma) from the same donor.
The Growing Demand for Disease-State Materials
The cell therapy industry is experiencing sharply rising demand for disease-state donor materials, driven by several converging trends. The expansion of autologous therapies into new disease areas — particularly autoimmune diseases like lupus, where companies are developing CAR-T and other cell-based approaches — is creating new requirements for patient-derived starting materials.[6] Simultaneously, the maturation of the field has produced a deeper understanding that process development conducted solely with healthy material does not adequately de-risk clinical manufacturing.[1]
Published research from apheresis product characterization studies now provides scoring systems that can predict manufacturing outcomes based on T cell phenotype at the time of collection.[3][4] This level of insight is only possible when development programs incorporate disease-state materials from the earliest stages.
Building Disease-State Materials into Your Development Strategy
The most effective approach integrates disease-state samples throughout the development lifecycle — not as a late-stage validation step, but as a foundational element of process design.[1] Starting with representative patient material during process development, testing manufacturing robustness against the full range of patient variability, and establishing specifications that account for disease-specific cellular characteristics all reduce the risk of costly failures during clinical manufacturing.
For cell therapy developers, the question is no longer whether to use disease-state starting materials, but how early and how comprehensively to incorporate them into the development program.
Ready to accelerate your cell therapy program? Contact OrganaBio at organabio.com to speak with our team.
References
[2] Reddy OL, Stroncek DF, Panch SR. “Improving CAR T cell therapy by optimizing critical quality attributes.” Seminars in Hematology, 2020;57(2):33–38. doi:10.1053/j.seminhematol.2020.07.005
[3] Bornstein S, et al. “Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.” Blood Advances, 2024;8(2):337–350. doi:10.1182/bloodadvances.2023011690
[4] Allen ES, et al. “Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.” Cytotherapy, 2022. doi:10.1016/j.jcyt.2022.05.003
[5] Cell & Gene Therapy Insights. “The importance of collection, processing & biopreservation best practices in determining CAR-T starting material quality.” Cell & Gene Therapy Insights, 2018.
[6] Lim WA, June CH. “The principles of engineering immune cells to treat cancer.” Cell, 2017;168(4):724–740. See also: Mackensen A, et al. “Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.” Nature Medicine, 2022;28:2124–2132.
